Candel (CADL) Stock Skyrockets Following Major Clinical Trial Milestone
Fahim Awan
December 11, 2024
With the release of encouraging primary endpoint findings from its phase 3 clinical study assessing CAN-2409 viral immunotherapy in localized prostate cancer, Candel Therapeutics, Inc.